Browse News
Filter News
Found 240 articles
-
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
-
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
3/12/2024
Nimbus Therapeutics, LLC today announced that Katharine Knobil, M.D., has been appointed to the Company’s Board of Directors.
-
The California-based biotech will use the Series C funding to move its TYK2 inhibitor into Phase III in plaque psoriasis this year in a potential challenge to Bristol Myers Squibb and Takeda.
-
Anagenex Expands Leadership Team with Appointment of Adrian Schreyer, Ph.D., as Chief Technology Officer
3/4/2024
Anagenex today announced the appointment of Adrian Schreyer, Ph.D., as Chief Technology Officer.
-
Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
2/28/2024
Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided its financial outlook for 2024.
-
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
2/2/2024
Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2023, which reflect strong pipeline acceleration, continued portfolio diversification, and momentum in our business.
-
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
2/1/2024
Takeda announced financial results for the third quarter of fiscal year 2023. With year-to-date strong momentum in its Growth & Launch Products offsetting the significant revenue impact of generic entrants, Takeda remains on track towards its full-year Management Guidance.
-
Schrödinger Provides Update on Progress Across the Business and Outlines 2024 Development and Operational Goals
1/8/2024
Schrödinger, Inc., Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, provided an update on its progress across the business and announced its development and operational goals for 2024.
-
Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline
1/5/2024
Nimbus Therapeutics , LLC announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.
-
Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications
12/18/2023
Anagenex and Nimbus Therapeutics announced they have initiated a research collaboration.
-
Nonalcoholic Steatohepatitis (NASH) Market to Observe Stunning Growth by 2032 Owing to a Robust Pipeline
11/1/2023
The NASH market is expected to evolve because of emerging therapies like MGL-3196, Semaglutide, Vonafexor, HPG1860, VK2809, BIO89-100, LPCN 1144, and others.
-
Nimbus Therapeutics Presents Positive Preliminary Data from Clinical Trial of HPK1 Inhibitor in Solid Tumors at SITC Annual Meeting
10/31/2023
Nimbus Therapeutics today announced initial data from the company’s ongoing Phase 1/2 study of NDI-101150, a small-molecule inhibitor of HPK1, which are being presented in a poster at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.
-
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
10/26/2023
Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2023, which reflect significant pipeline progress and advances in the company's portfolio renewal strategy.
-
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
10/26/2023
Takeda announced financial results for the first half of fiscal year 2023, updating reported and Core forecasts and reconfirming Management Guidance for Core change at CER.
-
The two biotech companies announced initial public offering pricing Thursday, respectively, with shares beginning trading Friday and valued at more than $560 million cumulatively.
-
Led by new investor Google Ventures, it is one of 2023’s larger fundraising efforts and comes less than a year after a $4 billion deal with Takeda for a Nimbus autoimmune disease treatment.
-
Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
9/6/2023
Nimbus Therapeutics, LLC announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines.
-
Schrödinger Reports Second Quarter 2023 Financial Results
8/2/2023
Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the quarter ended on June 30, 2023.
-
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7/27/2023
Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2023, which reflect continued execution against our strategic priorities.
-
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
7/27/2023
Takeda announced strong financial results for the first quarter of fiscal year 2023. Takeda chief financial officer, Costa Saroukos, commented: “Our Growth & Launch Products continued to drive revenue growth in the first quarter of FY2023, contributing to a core operating profit margin of 30.8%.